Your browser doesn't support javascript.
loading
[Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients].
Dronova, T A; Babyshkina, N N; Zavyalova, M V; Slonimskaya, E M; Cherdyntseva, N V.
Affiliation
  • Dronova TA; Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.
  • Babyshkina NN; National Research Tomsk State University, Tomsk, 634050 Russia.
  • Zavyalova MV; tanyadronova@mail.ru.
  • Slonimskaya EM; Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009 Russia.
  • Cherdyntseva NV; National Research Tomsk State University, Tomsk, 634050 Russia.
Mol Biol (Mosk) ; 55(1): 118-125, 2021.
Article in Ru | MEDLINE | ID: mdl-33566031
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Vascular Endothelial Growth Factor A Type of study: Prognostic_studies Limits: Humans Language: Ru Journal: Mol Biol (Mosk) Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Vascular Endothelial Growth Factor A Type of study: Prognostic_studies Limits: Humans Language: Ru Journal: Mol Biol (Mosk) Year: 2021 Type: Article